ArticleDermatologie (Heidelberg, Germany)2025
[Principles of antimicrobial stewardship].
Article in Dermatologie (Heidelberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The global emergence of multiresistant pathogens threatens the effectiveness of antimicrobial therapies and calls for a rational use of antibiotics, antivirals, and antifungals. The main reason for the development of resistance is the inappropriate use of these substances in human and veterinary medicine and agriculture. Antimicrobial stewardship (AMS) combines strategies for optimizing prescribing practices in order to prevent the development of resistance, ensure successful treatment, and minimize side effects. Central elements are evidence-based guidelines, interdisciplinary visits, infectious disease consults, targeted training, feedback systems, and digital support. AMS is becoming increasingly established in Germany, but many antibiotics are still not prescribed in line with guidelines. Correct diagnosis, guideline-based empirical therapy, regular re-evaluation, dose adjustment, early oral administration, and outpatient parenteral anti-infective therapy (OPAT) are essential. Short, individually adapted treatment durations improve tolerability and reduce resistance pressure. AMS links epidemiological data with patient-specific factors and is key in personalized infection medicine. Only the consistent integration of AMS measures into everyday clinical practice can ensure the sustained efficacy of antimicrobial substances and improve the quality of patient care in the long term.
Indexed as
Identifiers
40643641What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.